Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2002 1
2003 1
2005 2
2007 1
2009 3
2010 2
2011 1
2013 2
2015 2
2016 1
2017 1
2018 2
2020 1
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
[Advanced Parkinson's disease: clinical characteristics and treatment (part 1)].
Kulisevsky J, Luquin MR, Arbelo JM, Burguera JA, Carrillo F, Castro A, Chacón J, García-Ruiz PJ, Lezcano E, Mir P, Martinez-Castrillo JC, Martínez-Torres I, Puente V, Sesar A, Valldeoriola-Serra F, Yañez R. Kulisevsky J, et al. Neurologia. 2013 Oct;28(8):503-21. doi: 10.1016/j.nrl.2013.05.001. Epub 2013 Jul 13. Neurologia. 2013. PMID: 23856182 Free article. Review. Spanish.
INTRODUCTION: A large percentage of patients with Parkinson's disease (PD) develop motor fluctuations, dyskinesias, and severe non-motor symptoms within 3 to 5 years of starting dopaminergic therapy, and these motor complications are refractory to treatment. …
INTRODUCTION: A large percentage of patients with Parkinson's disease (PD) develop motor fluctuations, dyskinesias, and …
Association of metals with the risk and clinical characteristics of Parkinson's disease.
Kim MJ, Oh SB, Kim J, Kim K, Ryu HS, Kim MS, Ayton S, Bush AI, Lee JY, Chung SJ. Kim MJ, et al. Parkinsonism Relat Disord. 2018 Oct;55:117-121. doi: 10.1016/j.parkreldis.2018.05.022. Epub 2018 May 28. Parkinsonism Relat Disord. 2018. PMID: 29891430
INTRODUCTION: While metals have been implicated in the pathophysiology of Parkinson's disease (PD), the clinical evidence is scarce. Further, the contribution of metals for the risk or clinical presentation of PD remains to be explored. METHODS: To investigate the a …
INTRODUCTION: While metals have been implicated in the pathophysiology of Parkinson's disease (PD), the clinical evidence is s …
Short- and long-term motor outcome of STN-DBS in Parkinson's Disease: focus on sex differences.
Golfrè Andreasi N, Romito LM, Telese R, Cilia R, Elia AE, Novelli A, Tringali G, Messina G, Levi V, Devigili G, Rinaldo S, Franzini AA, Eleopra R. Golfrè Andreasi N, et al. Neurol Sci. 2022 Mar;43(3):1769-1781. doi: 10.1007/s10072-021-05564-w. Epub 2021 Sep 9. Neurol Sci. 2022. PMID: 34499244
INTRODUCTION: Subthalamic nucleus deep brain stimulation (STN-DBS) is an established treatment for patients with Parkinson's disease (PD) with motor complications; the contribution of sex in determining the outcome is still not understood. ...Males showed a s …
INTRODUCTION: Subthalamic nucleus deep brain stimulation (STN-DBS) is an established treatment for patients with Parkinson's disea …
MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
Sampaio TF, Dos Santos EUD, de Lima GDC, Dos Anjos RSG, da Silva RC, Asano AGC, Asano NMJ, Crovella S, de Souza PRE. Sampaio TF, et al. J Clin Pharmacol. 2018 Jul;58(7):920-926. doi: 10.1002/jcph.1096. Epub 2018 Mar 26. J Clin Pharmacol. 2018. PMID: 29578580 Free article.
The most commonly used Parkinson's disease (PD) treatment is the replacement of dopamine by its levodopa precursor (l-dopa). ...After multivariate analysis, we observed a significant difference between PD groups for the following variables: sex (P = .0 …
The most commonly used Parkinson's disease (PD) treatment is the replacement of dopamine by its levodopa precursor (l-d …
Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study.
Zappia M, Annesi G, Nicoletti G, Arabia G, Annesi F, Messina D, Pugliese P, Spadafora P, Tarantino P, Carrideo S, Civitelli D, De Marco EV, Cirò-Candiano IC, Gambardella A, Quattrone A. Zappia M, et al. Arch Neurol. 2005 Apr;62(4):601-5. doi: 10.1001/archneur.62.4.601. Arch Neurol. 2005. PMID: 15824260 Clinical Trial.
BACKGROUND: Several factors, both clinical and genetic, may account for the risk of developing levodopa-induced peak-dose dyskinesias (PDD) in patients with Parkinson disease, but it is unclear how these factors interact for modulating the individual s …
BACKGROUND: Several factors, both clinical and genetic, may account for the risk of developing levodopa-induced peak-dose dyskines …
The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease.
De Letter M, Santens P, De Bodt M, Van Maele G, Van Borsel J, Boon P. De Letter M, et al. Clin Neurol Neurosurg. 2007 Jul;109(6):495-500. doi: 10.1016/j.clineuro.2007.04.003. Epub 2007 May 16. Clin Neurol Neurosurg. 2007. PMID: 17509751
OBJECTIVES: Hypokinetic dysarthria is commonly encountered in Parkinson's disease (PD). Although the etiology of this dysarthria is multifactorial, disorders of respiration may strongly contribute to it. ...However, this improvement is not solely the consequence of …
OBJECTIVES: Hypokinetic dysarthria is commonly encountered in Parkinson's disease (PD). Although the etiology of this dysarthr …
Prevalence and correlates of sleep disorders in Parkinson's disease: a polysomnographic study.
Alatriste-Booth V, Rodríguez-Violante M, Camacho-Ordoñez A, Cervantes-Arriaga A. Alatriste-Booth V, et al. Arq Neuropsiquiatr. 2015 Mar;73(3):241-5. doi: 10.1590/0004-282X20140228. Arq Neuropsiquiatr. 2015. PMID: 25807131 Free article.
OBJECTIVE: Sleep disorders in Parkinson's disease are very common. Polysomnography (PSG) is considered the gold standard for diagnosis. ...RESULTS: Ninety-four (78.3%) patients had an abnormal PSG. Half of the patients fulfilled criteria for sleep apnea-hypop …
OBJECTIVE: Sleep disorders in Parkinson's disease are very common. Polysomnography (PSG) is considered the gold standard for d …
Microstructure of Brain Nuclei in Early Parkinson's Disease: Longitudinal Diffusion Kurtosis Imaging.
Welton T, Hartono S, Shih YC, Lee W, Chai PH, Chong SL, Ng SYE, Chia NSY, Choi X, Heng DL, Tan EK, Tan LCS, Chan LL. Welton T, et al. J Parkinsons Dis. 2023;13(2):233-242. doi: 10.3233/JPD-225095. J Parkinsons Dis. 2023. PMID: 36744346 Free PMC article.
BACKGROUND: Diffusion kurtosis imaging provides in vivo measurement of microstructural tissue characteristics and could help guide management of Parkinson's disease. ...RESULTS: At baseline, mean kurtosis was higher in Parkinson's disease than c …
BACKGROUND: Diffusion kurtosis imaging provides in vivo measurement of microstructural tissue characteristics and could help guide ma …
Sex Is the Main Determinant of Levodopa Clinical Pharmacokinetics: Evidence from a Large Series of Levodopa Therapeutic Monitoring.
Contin M, Lopane G, Belotti LMB, Galletti M, Cortelli P, Calandra-Buonaura G. Contin M, et al. J Parkinsons Dis. 2022;12(8):2519-2530. doi: 10.3233/JPD-223374. J Parkinsons Dis. 2022. PMID: 36373294 Free PMC article.
BACKGROUND: Different studies, mostly with limited cohorts, have suggested the effects of patients' characteristics on levodopa (LD) pharmacokinetics. OBJECTIVE: We primarily aimed at investigating in a large population the relationship between patients' features an …
BACKGROUND: Different studies, mostly with limited cohorts, have suggested the effects of patients' characteristics on levodopa …
Gender and the Parkinson's disease phenotype.
Baba Y, Putzke JD, Whaley NR, Wszolek ZK, Uitti RJ. Baba Y, et al. J Neurol. 2005 Oct;252(10):1201-5. doi: 10.1007/s00415-005-0835-7. Epub 2005 Sep 12. J Neurol. 2005. PMID: 16151602
OBJECTIVES: To determine whether there are gender differences in the Parkinson's disease (PD) phenotype using a large clinic-based cohort. ...CONCLUSIONS: The majority of comparisons tended to highlight the commonalities in the PD phenotype between genders, particul …
OBJECTIVES: To determine whether there are gender differences in the Parkinson's disease (PD) phenotype using a large clinic-b …
21 results